PRLX 93936

Drug Profile

PRLX 93936

Alternative Names: Erastin analogue; PRLX 82845; PRLX93936

Latest Information Update: 22 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Columbia University; Whitehead Institute for Biomedical Research
  • Developer Prolexys Pharmaceuticals
  • Class Quinazolinones; Small molecules
  • Mechanism of Action Ion channel modulators; Ras protein inhibitors; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2012 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy) in USA (IV)
  • 01 Nov 2011 Prolexys completes a phase I trial in Advanced solid tumours in USA (NCT00528047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top